Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Upper Respiratory Drugs: Antitussives, Expectorants, and Mucolytics

Upper Respiratory Drugs: Antitussives, Expectorants, and Mucolytics

Respiratory symptoms, such as congestion and cough, commonly accompany respiratory tract conditions. Various medications, such as antitussives, expectorants, and mucolytics, play crucial roles in providing relief.
Antitussives include codeine, dextromethorphan (Robitussin), and benzonatate (Tessalon). Codeine and dextromethorphan exert their effects centrally by suppressing the cough reflex center in the medulla. Benzonatate operates peripherally within the respiratory tract by anesthetizing...

Drugs Used in Upper Respiratory Disorders: Overview

Drugs Used in Upper Respiratory Disorders: Overview

Upper respiratory tract disorders, including viral infections and allergic rhinitis, cause significant discomfort and disrupt daily life. Managing these conditions involves a variety of drugs, such as antihistamines, intranasal steroids, decongestants, antitussives, expectorants, and mucolytics. Specific examples of drugs in each category are provided.
Antihistamines (e.g., Benadryl) block histamines from binding. Histamines are chemicals released during an allergic reaction in the body. As a...

Drugs Used in Lower Respiratory Disorders: Overview

Drugs Used in Lower Respiratory Disorders: Overview

Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...

Chronic Obstructive Pulmonary Disease-V: Management

Chronic Obstructive Pulmonary Disease-V: Management

Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation

COPD: Management Using Bronchodilators and Corticosteroids

COPD: Management Using Bronchodilators and Corticosteroids

Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...

Adrenergic Agonists: Therapeutic Classification

Adrenergic Agonists: Therapeutic Classification

Adrenergic agonists can be classified based on their therapeutic uses and mechanisms of action. They serve various purposes in clinical applications.
Vasopressor or pressor agents: They increase blood pressure and function as cardiac stimulants. Examples include endogenous catecholamines (norepinephrine and dopamine) and synthetic agents (phenylephrine).
Bronchodilators: β2-agonists can relax bronchial muscles and widen airways. They are commonly used for treating obstructive pulmonary...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Reply to: Is the role of eosinophils in refractory chronic cough truly dismissed? Mepolizumab reduced blood and sputum eosinophils, but not eosinophil-derived neurotoxin.

The European respiratory journal·2026

Same author

Ventilator Control Variables: Pressure Control, Volume Control, and Adaptive Targeting of Pressure Control.

NeoReviews·2026

Same author

Assessing the reliability of upper airway sampling for microbiological surveillance in cystic fibrosis.

Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society·2025

Same author

Mepolizumab for the treatment of refractory chronic cough in patients with eosinophilic airways disease (MUCOSA): a randomised, double-blind, parallel-group, placebo-controlled trial.

The European respiratory journal·2025

Same author

Reply to Zeng: the SOOTHE trial of camlipixant in RCC: a cautionary note on stratification and relevance.

American journal of respiratory and critical care medicine·2025

Same author

The NEuroCOUGH Chronic Cough Registry: a protocol for a pan-European observational study.

ERJ open research·2025

Search research articles

Related Experiment Video

Updated: May 31, 2026

Methods for Detecting Cough and Airway Inflammation in Mice

Methods for Detecting Cough and Airway Inflammation in Mice

Published on: August 2, 2024

Pharmacologic therapy for cough.

Emma C Young¹, Jaclyn A Smith

¹Respiratory Research Group, Faculty of Medicine and Human Sciences, The University of Manchester, Manchester Academic Health Science Centre, University Hospital of South Manchester NHS Foundation Trust, Manchester, UK.

Current Opinion in Pharmacology

|July 5, 2011

Summary

This summary is machine-generated.

Effective cough medicines are needed, but development is hindered by limited understanding of cough mechanisms and a lack of assessment tools. This review examines current anti-tussive agents using a mechanism-based approach.

More Related Videos

Establishment of a Mouse Model with Cough Hypersensitivity via Inhalation of Citric Acid

Establishment of a Mouse Model with Cough Hypersensitivity via Inhalation of Citric Acid

Published on: January 10, 2025

Ginger Moxibustion, A Non-pharmacological Treatment, for Diarrhea in Patients with Chronic Obstructive Pulmonary Disease

Ginger Moxibustion, A Non-pharmacological Treatment, for Diarrhea in Patients with Chronic Obstructive Pulmonary Disease

Published on: December 27, 2024

Related Experiment Videos

Last Updated: May 31, 2026

Methods for Detecting Cough and Airway Inflammation in Mice

Methods for Detecting Cough and Airway Inflammation in Mice

Published on: August 2, 2024

Establishment of a Mouse Model with Cough Hypersensitivity via Inhalation of Citric Acid

Establishment of a Mouse Model with Cough Hypersensitivity via Inhalation of Citric Acid

Published on: January 10, 2025

Ginger Moxibustion, A Non-pharmacological Treatment, for Diarrhea in Patients with Chronic Obstructive Pulmonary Disease

Ginger Moxibustion, A Non-pharmacological Treatment, for Diarrhea in Patients with Chronic Obstructive Pulmonary Disease

Published on: December 27, 2024

Area of Science:

Pharmacology
Respiratory Medicine
Clinical Therapeutics

Background:

Cough is a prevalent symptom, yet effective treatments are scarce, representing a significant unmet medical need.
Development of anti-tussive agents is limited by incomplete understanding of cough mechanisms and the distinction between pathological cough and protective reflex.
A lack of validated tools for cough assessment further impedes research and pharmaceutical investment.

Purpose of the Study:

To review the clinical evidence for anti-tussive activity of currently available agents.
To adopt a mechanism-based approach to evaluating existing cough treatments.

Main Methods:

Literature review of clinical studies on anti-tussive agents.
Analysis of pharmacological mechanisms underlying cough suppression.
Evaluation of evidence based on disease-specific cough triggers and protective reflex roles.

Main Results:

Discussion of clinical evidence for various anti-tussive agents.
Identification of limitations in current treatment options.
Highlighting the gap between understanding cough mechanisms and therapeutic development.

Conclusions:

A mechanism-based approach is crucial for understanding the efficacy of anti-tussive agents.
Further research into cough pathophysiology is needed to drive innovation in treatment.
Addressing the unmet need for effective, well-tolerated cough medicines requires a deeper mechanistic understanding and improved assessment tools.